|1.||Flake, Zachary A: 2 articles (03/2015 - 03/2004)|
|2.||Silberstein, Stephen D: 2 articles (01/2010 - 09/2008)|
|3.||Siddiqui, Emad J: 2 articles (10/2006 - 03/2006)|
|4.||Thompson, Cecil S: 2 articles (10/2006 - 03/2006)|
|5.||Mikhailidis, Dimitri P: 2 articles (10/2006 - 03/2006)|
|6.||Mumtaz, Faiz H: 2 articles (10/2006 - 03/2006)|
|7.||Bergman, Joseph: 2 articles (03/2006 - 11/2004)|
|8.||Miodownik, Chanoch: 2 articles (03/2006 - 11/2004)|
|9.||Statsenko, Nikolay: 2 articles (03/2006 - 11/2004)|
|10.||Lerner, Vladimir: 2 articles (03/2006 - 11/2004)|
02/01/1999 - "The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. "
02/01/1999 - "In this randomized study, the efficacy of a single dose of three serotonin antagonists were compared in prophylaxis of acute and delayed vomiting induced by moderately emetogenic, single-day chemotherapy in chemotherapy-naïve patients. "
02/01/1999 - "The authors conclude that there may be clinically important differences among serotonin antagonists used for chemotherapy-induced emesis."
06/01/1998 - "In recent years, the management of chemotherapy-induced emesis in children has been greatly modified by the introduction of a new therapeutic class: serotonin antagonists. "
05/01/1993 - "Development of serotonin antagonists for the control of chemotherapy-induced emesis."
01/01/2012 - " 5-HT antagonists, we found a reduction in intraoperative nausea (average risk ratio (RR) 0.64, 95% confidence interval (CI) 0.46 to 0.88, eight studies, 720 women). "
11/01/2004 - "The use of selective serotonin antagonists in the palliation of intractable nausea: implications for the clinical nurse specialist."
04/15/2007 - "5-Hydroxytryptamine antagonists are effective in controlling acute nausea associated with chemotherapy. "
03/01/2014 - "Serotonin antagonists for nausea and vomiting."
12/01/2010 - "Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting."
02/13/1989 - "The newly developed and still experimental serotonin antagonists have initially shown very promising results but further studies are required to define their role in the antiemetic treatment with cancer chemotherapy. "
03/01/1981 - "The anorexia of cancer patients might be caused by tumor-induced alterations in the metabolism of the host which might be medically altered by serotonin-antagonists."
07/08/2004 - "The antiproliferative effect of serotonin-reuptake inhibitors (SSRI) and serotonin antagonists has been demonstrated in prostate tumors. "
02/01/1992 - "A new class of antiemetic agents, the serotonin antagonists, of which ondansetron is the first to be commercially available, promises significantly better control of the various emetic syndromes caused by cancer chemotherapy, with fewer side effects. "
01/01/2008 - "Drugs are the mainstay of treatment in terminal cancer, and the main classes of antiemetic agents are prokinetics, dopamine antagonists, antihistamines, anticholinergics and serotonin antagonists. "
|4.||Parkinsonian Disorders (Parkinsonism)
01/01/1986 - "Although mianserin was ineffective in chronic neuroleptic-induced parkinsonism, it cannot be excluded that 5-HT antagonists may be effective in the treatment of acute extrapyramidal side effects."
01/01/1990 - "Treatment trials of serotonin antagonists in Parkinson's disease and neuroleptic-induced Parkinsonism have been disappointing, with the possible exception of akathisia which has been reported to respond favorably to ritanserin. "
12/03/1985 - "Pretreatment with the 5-HT antagonists cyproheptadine and mianserin increased amphetamine-induced locomotor activity, reactivity and repetitive movements and decreased haloperidol-induced dystonia and parkinsonism. "
|5.||Schizophrenia (Dementia Praecox)
07/01/2010 - "Key search terms included ondansetron, Zofran, serotonin antagonists, 5-HT(3) serotonin receptor, and schizophrenia. "
02/01/1998 - "The evolution of a new drug treatment for schizophrenia commenced with the observation that chlorpromazine possessed "neuroleptic" activity and progressed through studies with various dopamine and serotonin antagonists to ultimately lead to the discovery of risperidone. "
02/01/2013 - "A th-fgfr1(tk-) transgenic mouse with impaired FGF receptor signaling establishes a number of important characteristics that mimic human schizophrenia - a neurodevelopmental origin, anatomical abnormalities at birth, a delayed onset of behavioral symptoms, deficits across multiple domains of the disorder and symptom improvement with typical and atypical antipsychotics, 5-HT antagonists, and nicotinic receptor agonists. "
|4.||Serotonin (5 Hydroxytryptamine)
|5.||Histamine Antagonists (Antihistamines)
|1.||Drug Therapy (Chemotherapy)
|2.||Fluid Therapy (Oral Rehydration Therapy)
|3.||Stem Cell Transplantation